PELTHOS THERAPEUTICS INC
PTHSNYSE AMERICANTrading Snapshot
- Day Range
- $20.83 – $21.02
- 52-Week Range
- $18.19 – $37.50
- Volume
- $1.72B
- Avg Volume
- $2.12B
- Shares Outstanding
- 3.5M
- Next Earnings
- Nov 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $17M
- Last Q Revenue
- $16M
- P/E Ratio
- -0.5
- P/S Ratio
- 1.7x
- EPS (TTM)
- $-20.22
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +429.3%
Why Investors Own PTHS
- ✓High-growth profile — revenue up +32.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 49% gross margin and 29% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PELTHOS THERAPEUTICS INC
PTHS
StockOtter · stockotter.spaceAbout PELTHOS THERAPEUTICS INC
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Pelthos Therapeutics Q2 Earnings Call Highlights
Pelthos Therapeutics NYSEAMERICAN: PTHS reported second-quarter revenue growth as prescriptions for its lead product, ZELSUVMI, increased following the treatment's July 2025 commercial launch. The company also discussed
Pelthos Therapeutics Inc. (PTHS) Q2 2026 Earnings Call Transcript
Pelthos Therapeutics Inc. (PTHS) Q2 2026 Earnings Call Transcript
Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates
Pelthos Therapeutics Inc. (PTHS) came out with a quarterly loss of $6.62 per share versus the Zacks Consensus Estimate of a loss of $3.02. This compares to a loss of $5.38 per share a year ago.
Pelthos Therapeutics Announces Second Quarter 2026 Financial Results
Zelsuvmi ® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026
Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026
DURHAM, N.C., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”
Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders
DURHAM, N.C., July 24, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS) (the “Company” or “Pelthos”) today announced that it will hold its 2026 Annual Meeting of Stockholders virtually on Tuesday,